Status:

COMPLETED

A Study to Evaluate the Different Doses of VAC52416 (ExPEC10V) in Japanese Adults

Lead Sponsor:

Janssen Pharmaceutical K.K.

Conditions:

Healthy

Eligibility:

All Genders

60-85 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to evaluate the safety and reactogenicity of different doses of extraintestinal pathogenic Escherichia coli 10 valent (ExPEC10V) in Japanese participants greater than or e...

Eligibility Criteria

Inclusion

  • Participant must be Japanese as determined by participant's verbal report
  • Must be healthy or medically stable, in the investigator's clinical judgment, as confirmed by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests performed at the screening visit
  • Willing and able to adhere to the lifestyle restrictions
  • Agrees not to donate blood until 12 weeks after receiving the study intervention
  • Must be willing to provide verifiable identification, has means to be contacted, and to contact the investigator during the study

Exclusion

  • Clinically significant illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature greater than or equal to (\>=) 38.0 degree Celsius (100.4 degree Fahrenheit ) within 24 hours prior to the administration of study intervention; enrollment at a later date is permitted (provided the screening window of 28 days is respected)
  • History of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence)
  • Known allergies, hypersensitivity, or intolerance to ExPEC10V or its excipients
  • Known allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine excipients
  • Contraindication to Intramuscular (IM) injections and blood draws example, bleeding disorders

Key Trial Info

Start Date :

March 13 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 24 2020

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT04306302

Start Date

March 13 2020

End Date

December 24 2020

Last Update

January 20 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

SOUSEIKAI PS Clinic

Fukuoka, Japan, 8120025